University of Kentucky
Dr. Natasha Kyprianou is a Professor of Urology, Pathology, Biochemistry and Toxicology & Cancer Biology at the University of Kentucky College of Medicine, where she holds the James F. Hardymon Chair in Urology Research at the NCI-designated Markey Cancer Center in Lexington, Kentucky. She is a translational researcher who received her undergraduate and graduate education at the University of London, University of Leeds and the University of Wales College of Medicine in the UK. She was fellowship-trained in Urologic Oncology at Johns Hopkins University in Baltimore and in Molecular Oncology at the Imperial Cancer Research Institute in London, England. Dr. Kyprianou’s research focuses on (a) the signaling network operated by transforming growth factor-β (TGF-β) during prostate cancer progression and its cross-talk with the androgen/androgen receptor axis in the emergence of castration-resistant prostate cancer (CRPC); (b) deregulation of apoptosis mechanisms leading to prostate cancer metastatic progression and therapeutic resistance; and (c) pharmacological development of new targeted therapeutics to overcome such resistance in advanced tumors.
Dr. Kyprianou is a passionate and celebrated mentor of young scientists and has a long service on numerous grant review panels at the NIH, Department of Defense, the American Cancer Society, the Irish Cancer Center and American Urological Association (AUA)- Urology Care Foundation. Dr. Kyprianou has been inducted into the Johns Hopkins Society of University Scholars. She is the recipient of the Dominique Chopin Distinguished Award in Urology Research from the European Association of Urology/Urological Research, the Meritorious Achievement Award by the Society of Basic Urologic Research (SBUR), and the Distinguished Alumna Award from the AUA /Urology Care Foundation.
Sunday, May 5
1:55 PM – 2:05 PM